Diffuse large B-cell lymphoma variants: an update

Narittee Sukswai, Kirill Lyapichev, Joseph D. Khoury, L. Jeffrey Medeiros

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, representing approximately one-third of all cases worldwide. In the World Health Organization (WHO) classification of lymphomas, most cases of DLBCL are designated as not otherwise specified (NOS). About 20% of cases, however, are designated as specific variants of DLBCL. These variants, 13 in total, are specified on the basis of distinctive morphological or immunophenotypic findings or distinctive biological or clinical issues associated with their diagnoses. In this review we discuss the following variants: T-cell/histiocyte-rich large B-cell lymphoma; ALK-positive large B-cell lymphoma; plasmablastic lymphoma; intravascular large B-cell lymphoma; large B-cell lymphoma with IRF4 rearrangement; primary mediastinal large B-cell lymphoma; primary cutaneous diffuse large B-cell lymphoma, leg type; primary diffuse large B-cell lymphoma of the central nervous system; diffuse large B-cell lymphoma associated with chronic inflammation; lymphomatoid granulomatosis; primary effusion lymphoma; and HHV8-positive diffuse large B-cell lymphoma, NOS. Two additional variants recognised in the WHO classification, EBV-positive diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer are discussed elsewhere in another review within this issue of Pathology. Although not recognised as a specific variant in the current WHO classification, primary testicular diffuse large B-cell lymphoma also has unique biological features and requires some modification of the standard treatment approach for patients with DLBCL. Therefore, we suggest that primary testicular diffuse large B-cell lymphoma also should be recognised as a specific variant of DLBCL in a future version of the WHO classification.

Original languageEnglish (US)
Pages (from-to)53-67
Number of pages15
JournalPathology
Volume52
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Human Herpesvirus 4
Lymphoma
Lymphomatoid Granulomatosis
Primary Effusion Lymphoma
Histiocytes
Ulcer
Leg
Central Nervous System

Keywords

  • Diffuse large B-cell lymphoma
  • World Health Organization classification
  • variants

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Diffuse large B-cell lymphoma variants : an update. / Sukswai, Narittee; Lyapichev, Kirill; Khoury, Joseph D.; Medeiros, L. Jeffrey.

In: Pathology, Vol. 52, No. 1, 01.2020, p. 53-67.

Research output: Contribution to journalReview article

Sukswai, Narittee ; Lyapichev, Kirill ; Khoury, Joseph D. ; Medeiros, L. Jeffrey. / Diffuse large B-cell lymphoma variants : an update. In: Pathology. 2020 ; Vol. 52, No. 1. pp. 53-67.
@article{53160f28ad7f4d66a80f1550fe7e75cf,
title = "Diffuse large B-cell lymphoma variants: an update",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, representing approximately one-third of all cases worldwide. In the World Health Organization (WHO) classification of lymphomas, most cases of DLBCL are designated as not otherwise specified (NOS). About 20{\%} of cases, however, are designated as specific variants of DLBCL. These variants, 13 in total, are specified on the basis of distinctive morphological or immunophenotypic findings or distinctive biological or clinical issues associated with their diagnoses. In this review we discuss the following variants: T-cell/histiocyte-rich large B-cell lymphoma; ALK-positive large B-cell lymphoma; plasmablastic lymphoma; intravascular large B-cell lymphoma; large B-cell lymphoma with IRF4 rearrangement; primary mediastinal large B-cell lymphoma; primary cutaneous diffuse large B-cell lymphoma, leg type; primary diffuse large B-cell lymphoma of the central nervous system; diffuse large B-cell lymphoma associated with chronic inflammation; lymphomatoid granulomatosis; primary effusion lymphoma; and HHV8-positive diffuse large B-cell lymphoma, NOS. Two additional variants recognised in the WHO classification, EBV-positive diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer are discussed elsewhere in another review within this issue of Pathology. Although not recognised as a specific variant in the current WHO classification, primary testicular diffuse large B-cell lymphoma also has unique biological features and requires some modification of the standard treatment approach for patients with DLBCL. Therefore, we suggest that primary testicular diffuse large B-cell lymphoma also should be recognised as a specific variant of DLBCL in a future version of the WHO classification.",
keywords = "Diffuse large B-cell lymphoma, World Health Organization classification, variants",
author = "Narittee Sukswai and Kirill Lyapichev and Khoury, {Joseph D.} and Medeiros, {L. Jeffrey}",
year = "2020",
month = "1",
doi = "10.1016/j.pathol.2019.08.013",
language = "English (US)",
volume = "52",
pages = "53--67",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma variants

T2 - an update

AU - Sukswai, Narittee

AU - Lyapichev, Kirill

AU - Khoury, Joseph D.

AU - Medeiros, L. Jeffrey

PY - 2020/1

Y1 - 2020/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, representing approximately one-third of all cases worldwide. In the World Health Organization (WHO) classification of lymphomas, most cases of DLBCL are designated as not otherwise specified (NOS). About 20% of cases, however, are designated as specific variants of DLBCL. These variants, 13 in total, are specified on the basis of distinctive morphological or immunophenotypic findings or distinctive biological or clinical issues associated with their diagnoses. In this review we discuss the following variants: T-cell/histiocyte-rich large B-cell lymphoma; ALK-positive large B-cell lymphoma; plasmablastic lymphoma; intravascular large B-cell lymphoma; large B-cell lymphoma with IRF4 rearrangement; primary mediastinal large B-cell lymphoma; primary cutaneous diffuse large B-cell lymphoma, leg type; primary diffuse large B-cell lymphoma of the central nervous system; diffuse large B-cell lymphoma associated with chronic inflammation; lymphomatoid granulomatosis; primary effusion lymphoma; and HHV8-positive diffuse large B-cell lymphoma, NOS. Two additional variants recognised in the WHO classification, EBV-positive diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer are discussed elsewhere in another review within this issue of Pathology. Although not recognised as a specific variant in the current WHO classification, primary testicular diffuse large B-cell lymphoma also has unique biological features and requires some modification of the standard treatment approach for patients with DLBCL. Therefore, we suggest that primary testicular diffuse large B-cell lymphoma also should be recognised as a specific variant of DLBCL in a future version of the WHO classification.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma, representing approximately one-third of all cases worldwide. In the World Health Organization (WHO) classification of lymphomas, most cases of DLBCL are designated as not otherwise specified (NOS). About 20% of cases, however, are designated as specific variants of DLBCL. These variants, 13 in total, are specified on the basis of distinctive morphological or immunophenotypic findings or distinctive biological or clinical issues associated with their diagnoses. In this review we discuss the following variants: T-cell/histiocyte-rich large B-cell lymphoma; ALK-positive large B-cell lymphoma; plasmablastic lymphoma; intravascular large B-cell lymphoma; large B-cell lymphoma with IRF4 rearrangement; primary mediastinal large B-cell lymphoma; primary cutaneous diffuse large B-cell lymphoma, leg type; primary diffuse large B-cell lymphoma of the central nervous system; diffuse large B-cell lymphoma associated with chronic inflammation; lymphomatoid granulomatosis; primary effusion lymphoma; and HHV8-positive diffuse large B-cell lymphoma, NOS. Two additional variants recognised in the WHO classification, EBV-positive diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer are discussed elsewhere in another review within this issue of Pathology. Although not recognised as a specific variant in the current WHO classification, primary testicular diffuse large B-cell lymphoma also has unique biological features and requires some modification of the standard treatment approach for patients with DLBCL. Therefore, we suggest that primary testicular diffuse large B-cell lymphoma also should be recognised as a specific variant of DLBCL in a future version of the WHO classification.

KW - Diffuse large B-cell lymphoma

KW - World Health Organization classification

KW - variants

UR - http://www.scopus.com/inward/record.url?scp=85075427842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075427842&partnerID=8YFLogxK

U2 - 10.1016/j.pathol.2019.08.013

DO - 10.1016/j.pathol.2019.08.013

M3 - Review article

C2 - 31735345

AN - SCOPUS:85075427842

VL - 52

SP - 53

EP - 67

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 1

ER -